The optimization of compound dosage, vehicle, delivery route, target exposure, as well as further testing in various models of cryptorchidism and diseases associated with bone loss are required to establish the pharmacological utility of identified RXFP2 agonists. This evidence concerns the gene RXFP2 and cryptorchidism.